Rheumatology

P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.

Rheumatology

Martin Rudwaleit, Matthew A Brown, Floris Alexander van Gaalen, Nigil Haroon, Lianne S Gensler, Carmen Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, Thomas Vaux, Katy White, Atul Deodhar, Dennis McGonagle, Irene van der Horst-Bruinsma

E089 Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial.

Rheumatology

Helena Marzo-Ortega, Juergen Braun, Ricardo Blanco, Lianne S Gensler, Filip van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen G H van de Sande, Désirée van der Heidje, Tingting Zhuang, Anna Stefanska, Aimee Readie, Hanno Richards, Atul Deodhar

P284 Certolizumab pegol-treated patients with non-radiographic axSpA demonstrate improvements in sleep quality and other patient reported outcomes.

Rheumatology

Raj Sengupta, Lianne Gensler, Jonathan Kay, Walter Maksymowych, Nigil Haroon, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Thomas Kumke, Atul Deodhar

P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA.

Rheumatology

Karl Gaffney, Atul Deodhar, Lianne Gensler, Jonathan Kay, Walter Maksymowych, Nigil Haroon, Robert Landewé, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Thomas Kumke, Désirée van der Heijde

EP38 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies.

Rheumatology

Nick Barkham, Georg Schett, Xenofon Baraliakos, Filip van den Bosch, Atul Deodhar, Lianne S Gensler, Mikkel ?stergaard, Shital Agawane, Ayan Das Gupta, Shephard Mpofu, Todd Fox, Adam Winseck, Abhijit Shete, Brian Porter

E098 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542).

Rheumatology

Robert Landewe, Desiree van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Bengt Hoepken, Karen Thomas, Lianne S Gensler